Recently Featured

Yeast-Based Cell-Free Expression Systems Offer Cost-Reduction Opportunities for Biopharma

May 26, 2026
Recent research indicates that optimizing cell-free expression systems could enable biopharmaceutical companies to significantly reduce protein production costs. The study highlights the potential of these systems, which allow biochemical reactions to occur independently of living cells, to serve as viable alternatives for large-scale protein manufacturing. According to Dr. Karen Polizzi from Imperial College London, cell-free…

Vetter Begins Construction of New Production Facility in Saarlouis, Germany

May 25, 2026
Vetter, a prominent Contract Development and Manufacturing Organization (CDMO), has commenced construction on a new production site in Saarlouis, Germany, as marked by a groundbreaking ceremony. The initial phase will focus on establishing a cutting-edge facility dedicated to the commercial production of injectable drugs across a 95-acre industrial site. With an investment nearing half a…

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition

May 25, 2026
Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, showcasing the efficacy of Novo Nordisk’s CagriSema in improving body composition among adults with obesity. This trial is pivotal as it not only highlights the potential of CagriSema as a therapeutic option but also reinforces the growing focus on body composition as a critical…

As Trump Arrives in China, Big Pharma CEOs Are Notably Absent

May 25, 2026
As President Trump lands in Beijing, a significant absence is felt among his business delegation—leaders from the pharmaceutical industry. This notable lack of representation raises questions about the current state of U.S.-China relations, particularly in the context of the ongoing trade tensions and regulatory challenges facing the pharma sector. The absence of Big Pharma CEOs…

Ongoing Cases